U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07589101) titled '5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors' on April 20.
Brief Summary: This study aims to evaluate a novel 5T4 targeted nanobody PET imaging tracer, 68Ga-MY, for the detection and evaluation of solid tumors.
The 5T4 oncofoetal antigen is considered a valuable tumor-associated antigen, which is expressed in many different cancers, but is rarely expressed in normal adult tissues. And cell surface expression of 5T4 is an important property for antibody-targeted therapies. It has been shown that 5T4 is expressed on tumour-initiating cells (TICs) and associated with worse clinical outcome. Moreover, decreased adherence...